How to Value a Pre-Revenue Startup (2026)

A pre-revenue startup has no sales to multiply, so no formula sets its value. Investors price it with risk-based frameworks: the Berkus Method, the Scorecard Method, the Risk Factor Summation Method, and the Venture Capital Method, all anchored to what comparable startups recently raised. The final number gets set in the negotiation, usually as a SAFE cap rather than a calculated price.

That last point trips up most first-time founders. You go looking for the way to calculate your valuation, and you find five different methods that give five different answers. None of them agree because none of them are math in the way a revenue multiple is math. They are structured guesses about risk. The real question an investor is answering is simpler: how much of this story is already proven, and how much is still hope they would be paying for?

This guide walks through the methods investors actually use on a company with zero revenue and explains the thing that decides your number more than any framework: how much proof you can put on the table before the conversation starts. The method you use matters less than that proof, because every method is just a way of pricing how much of your story is already real.

Two terms run through everything below, so here they are in plain English. Pre-money is your company's value just before new money goes in. A SAFE cap is the highest valuation at which an early investor's money turns into shares in a later round.

Why there is no formula for a pre-revenue startup

The standard ways to value a company all need a number you do not have yet. A revenue multiple needs revenue. A discounted cash flow model needs cash flow. An earnings multiple needs earnings. A pre-revenue startup has none of these. Equidam, a valuation platform that ran more than 3,000 startup valuations in the first half of 2025, defines pre-seed as companies with no fully built product, often nothing beyond an MVP, raising their first institutional round with no venture investors on the cap table (Equidam, Startup Valuation Delta H1 2025). There is nothing to put in a spreadsheet.

So founders reach for five-year financial projections instead. Here is the problem with that. A five-year forecast for a company with no customers is a chain of assumptions, each one multiplied by the next. The conversion rate is a guess. The growth rate is a guess stacked on the guess. By year three the model is fiction with decimal points. Dave Berkus, the angel investor who built the most widely used pre-revenue method in the 1990s, designed it specifically because he had never seen an early-stage company hit the projections in its plan (MicroVentures, The Berkus Valuation Method).

That is why early-stage investors quietly ignore the forecast and price the risk instead. Every method below asks the same question a different way: where is this company on the path from idea to proven business, and what has the market recently paid for companies at that point?

The five methods investors use to value a pre-revenue startup

Four of these methods are qualitative, scoring what you can judge before there is revenue: team, product, market, and risk. The fifth works backward from a future exit. Here is what each measures, with detail below.

The Berkus Method

The Berkus Method assigns up to $500,000 of value to each of five things: a sound idea, a working prototype, a quality management team, strategic relationships, and a clear path to product rollout or sales. Add them up and the ceiling is $2.5 million in pre-money value (MicroVentures). A worked example: say a founder has a solid idea worth $400,000, a working prototype at $500,000, a strong team at $400,000, early partnerships at $300,000, and a clear path to first sales at $300,000. That sums to a $1.9 million pre-money valuation. The cap keeps the conversation on risks the founder has actually retired, like a built prototype or a hired technical lead, and it is the method angels reach for first on the earliest deals.

The Scorecard Method

The Scorecard Method adjusts the median pre-money valuation of comparable startups in your region and sector up or down, based on how your company compares on a weighted set of factors, with the team weighted most heavily at up to 30 percent. It was built by Bill Payne, named the Angel Capital Association's Angel Investor of the Year in 2009 (Angel Capital Association, Scorecard Valuation Methodology). If a comparable median is $4.5 million and your weighted factors come out about 15 percent above average, your number lands at roughly $5.2 million. The method is only as good as the comparable data behind it, which is why founders should know what recent pre-seed rounds in their space actually closed at.

The Risk Factor Summation Method

This one is the most granular. It starts with a baseline regional valuation and then scores twelve separate risk areas, from management and stage of business to manufacturing, sales, funding, competition, technology, litigation, and the odds of a profitable exit. Each factor is scored from minus two (very high risk) to plus two (very low risk), and each step moves the valuation by about $250,000 (Rho, Risk Factor Summation Method Explained). A startup with a strong team but a crowded market and heavy regulation might score positive on management and negative on competition and legislation, netting out close to baseline. The strength of the method is that it makes you name every risk out loud. The weakness is that the scores are subjective and the same risk can sneak in twice.

The Venture Capital Method

The Venture Capital Method, introduced by Professor Bill Sahlman at Harvard Business School in 1987, is the one that works backward (Harvard Business School, The Venture Capital Method). It starts with an estimated exit value five to eight years out, then divides by the return the investor needs to hit. Post-money valuation equals terminal value divided by the anticipated return on investment. In plain terms, the investor estimates what you might sell for one day, then works backward to what they can pay now and still hit their fund's target return. An investor expecting a 10x return on a company they think could sell for $100 million would back into a $10 million post-money today, then subtract their check to get the pre-money. The honest problem at pre-revenue is that both inputs, the exit price and the return multiple, are guesses. It tells you more about the investor's fund math than about your company.

Comparable transactions

Underneath all four frameworks sits the same reality check that every experienced investor returns to: what did similar companies actually raise at recently. Carta's data shows the standard pre-seed instrument in 2025 was a post-money SAFE with a valuation cap and no discount, with median caps clustering around $10 million for rounds between $250,000 and $1 million, and around $15 million for rounds between $1 million and $2.5 million (Carta, State of Pre-Seed 2025). Comparable data is powerful and also dangerous, because comps move with the market cycle: hot in a boom, cold in a correction, and right now we are in a correction.

Which investor uses which method

The method you face depends on who is across the table. Angels and angel groups lean on the Berkus Method and the Scorecard Method, both built for early-stage angels. Seed funds lean on the Venture Capital Method and comparable transactions, because they think in fund returns. Accelerators often skip the math and offer one standard cap across a batch. A solo angel and a seed fund can land far apart on the same startup, so know which language your investor speaks before you walk in.

What investors are actually doing with these methods

Here is the part the framework lists never say out loud. An investor uses these methods to price how much risk they are taking on and to put structure around a conversation that is mostly about uncertainty. Each method converts "this is early and unproven" into a dollar range both sides can negotiate around. That is why the methods disagree, and why the disagreement matters less than it looks. Berkus might say $2 million, the Scorecard $5 million off a frothy comparable set, the VC Method $3 million off a conservative exit. The investor takes the spread, weighs it against recent deals, and proposes a cap.

This is why arguing about which method is "correct" is a losing game. The winning move is to shrink the uncertainty the methods are pricing. Every risk you have retired and every assumption you have turned into evidence pulls the range upward, because you give the investor more proof to underwrite.

The number you negotiate is usually a SAFE cap

For most pre-revenue rounds in 2026, you negotiate a SAFE cap. A priced valuation comes later, once there is traction to value. SAFEs made up roughly 90 percent of pre-seed deals on Carta in early 2025, and the post-money SAFE with a cap and no discount is the default instrument (Carta, State of Pre-Seed 2025). The cap is the maximum valuation at which the investor's money will convert to equity later. It behaves like a valuation in the negotiation, though it is really a ceiling on a future conversion.

This is the practical heart of pre-revenue valuation. A SAFE cap lets both sides avoid pinning down an exact value for a company that cannot be valued precisely yet. You agree on a reasonable ceiling, the money goes in, and the real price gets set at the priced round that follows. For the full mechanics of how the cap converts and what pre-money versus post-money does to your ownership, see our guide to pre-money versus post-money valuation, and the instrument is broken down in the convertible note versus SAFE comparison.

Because the cap is a negotiation, three things move it far more than any framework: your team, your comparable set, and the proof you walk in with.

What actually sets a pre-revenue valuation

If the methods are just structured risk translation, what really decides the number? Three forces, in order of weight.

First, the team. With no product traction to point to, the founders are the single largest piece of evidence in the room. Across a survey of 885 venture capitalists published in the Journal of Financial Economics, 47 percent ranked the team as the most important factor in their decision, ahead of product, market, or business model (Gompers et al., How Do Venture Capitalists Make Decisions, JFE 2020). At pre-revenue, that weighting goes even higher, because the team is most of what there is to judge. This is also why repeat founders raise at higher numbers on less. Crunchbase analysis shows previously successful founders succeed at roughly 30 percent versus 18 percent for first-timers, and they negotiate better terms and less dilution as a result (Crunchbase, repeat founder data). A proven team is itself retired risk.

Second, the comparable set and the market cycle. Your valuation does not float free. It sits inside whatever the market is currently paying for companies at your stage, and that anchor moves. PitchBook found that nearly 25 percent of US venture rounds in 2024 were flat or down, a decade high and more than double the 12 percent rate of 2022 (PitchBook, 2024 flat and down rounds). When later-stage valuations compress, early-stage caps feel the pull. The median seed pre-money valuation still rose to $16 million in Q3 2025 on Carta, up 14 percent year over year, but that headline hides wide dispersion and a tougher climate for companies without a clear story (Carta, State of Private Markets Q3 2025). Geography moves the baseline too. Outside the US, pre-seed valuations run lower; Equidam's H1 2025 data put average pre-seed valuations in Latin America, Southeast Asia, and Africa between $2.1 million and $2.2 million (Equidam H1 2025).

Third, the proof you can show. This is the only force fully in your control. Demonstrated demand, a working product, signed letters of intent, a waitlist with real engagement, a technical edge that is hard to copy: each converts a line in your pitch from a claim into evidence. Investors are increasingly explicit about wanting this. Equidam's H1 2025 data describes a market where investors demand demonstrable unit economics and a credible go-to-market plan even from very early companies (Equidam H1 2025). Proof separates two identical-looking decks into a $3 million cap and a $6 million one.

The repetition trap that drags pre-revenue valuations down

Here is what makes the pre-revenue valuation conversation so exhausting. Because nothing is proven in advance, every investor re-derives your number from scratch. Each fund runs its own version of the methods above, asks the same questions, and arrives at its own cap. Conviction does not transfer, so the next investor starts from zero.

For the founder, this means defending the same assumptions in fifteen separate meetings, watching the number swing depending on who is in the room that week. Academic work calls this snowballing: valuation signals accumulate and reinforce each other over time, and the number can drift away from the company's fundamentals entirely. A 2025 systematic review of startup valuation signals documented the pattern (Taylor and Francis, snowballing signaling theory in startup valuation, 2025). When perception drives the number, it swings with perception. One enthusiastic lead and your cap jumps; one skeptical week and it sinks. None of it is anchored, because the proof was never established up front.

The way out of the swing is to fix the anchor. If every investor sees the same structured evidence before the conversation, the methods stop pulling in five directions and start converging, because they are all pricing the same proven facts instead of each investor's private read on the unknowns.

The proof layer

This is where a structured proof layer changes the conversation. SeedForge gives a pre-revenue founder one 30-minute AI session that turns scattered evidence into a Living Profile: the team's real track record, the market signal, the early usage or letters of intent, and a clear plan for the money. The founder shares one link, and every investor opens the same evidence before the first call.

The valuation talk still happens. It simply starts from what is real instead of from a blank spreadsheet and a round number. Investors anchor faster when the proof is in front of them, and the founder stops re-defending the same assumptions in meeting after meeting. The methods above still run, but they run against a shared, structured set of facts, which is exactly what pulls a swinging pre-revenue number back toward evidence. See how it works at seedforge.com.

A practical pre-revenue valuation checklist

Before you walk into a single valuation conversation, work through this.

1. Pull your comparable set. Find five to ten recent pre-seed rounds in your sector and region. Note the actual SAFE caps; the headline numbers can mislead. Carta's pre-seed data and recent deal announcements are your anchor. This is the number every method circles back to.

2. Run two methods, then stop. The Berkus Method and the Scorecard Method are enough to bracket a sane range for most software startups. If your investor thinks in fund returns, sketch the Venture Capital Method too so you can speak their language.

3. List your retired risks. Write down every risk you have already removed: a built prototype, a technical co-founder, a signed pilot, a waitlist with real usage. Each one is a point you can push the range up on, because it turns a promise into proof.

4. Decide your cap range before the meeting, not during it. Know your floor and your target. Anchor the target to comparables plus your retired risks, and be ready to show why.

5. Do not over-optimize the cap. A cap set too high creates a down round later when you cannot grow into it, and down rounds are at a decade high (PitchBook). A lower cap with a fast close and room to step up usually wins.

6. Bring the proof that backs the number. The fastest way to defend a number is to make the evidence behind it impossible to argue with. Structured proof of early traction does more for your cap than any framework. If you are pre-revenue and unsure what counts as traction, our guide on how to prove traction when you are pre-revenue breaks it down.

Once you have revenue, the methods shift toward multiples and the conversation changes. For the post-traction picture, see our guide to seed-stage startup valuation.

FAQ

How do you value a startup with no revenue?

With no revenue to multiply, investors price the risk. They use qualitative frameworks like the Berkus Method, the Scorecard Method, the Risk Factor Summation Method, and the Venture Capital Method, then anchor the result to what comparable startups recently raised. The final number is negotiated, usually as a SAFE cap rather than a calculated price.

What is a typical pre-revenue valuation in 2026?

For pre-seed rounds, Carta data shows the standard instrument is a post-money SAFE with a cap and no discount, with median caps around $10 million for rounds of $250,000 to $1 million, and around $15 million for rounds of $1 million to $2.5 million. Your specific cap depends on team, comparables, and proof, and ranges widely.

Do I need financial projections to value a pre-revenue startup?

You will be asked for them, but experienced early-stage investors weight them lightly. A five-year forecast with no customers is a chain of assumptions. Investors discount it heavily and price your risk instead, which is why retired risks and real evidence move your number far more than a polished model.

Which pre-revenue valuation method is the most accurate?

None is accurate in the way a revenue multiple is, because there is no revenue to anchor to. Each method is a structured estimate of risk. The most reliable practical anchor is comparable transactions: what similar startups in your sector and region actually raised at recently. Use a method to bracket the range, then sanity-check against real comps.

How much does the founding team affect a pre-revenue valuation?

A great deal. With no product traction, the team is the largest piece of evidence available. In the Gompers survey of 885 venture capitalists, 47 percent ranked team as the single most important factor, and that weighting rises at pre-revenue. Repeat founders with a prior success raise at higher caps with less dilution as a direct result.

Is a SAFE cap the same as a valuation?

A SAFE cap is close, though it works differently. It is the maximum valuation at which an investor's money converts to equity in a future priced round. It behaves like a valuation in the negotiation, while really being a ceiling on a later conversion. Most pre-revenue rounds use a cap precisely because the company cannot be priced precisely yet.

Bottom line

There is no formula that values a pre-revenue startup, because there is no revenue to put in one. Investors price the risk with the Berkus, Scorecard, Risk Factor Summation, and Venture Capital methods, anchor the result to recent comparable deals, and settle on a SAFE cap in the negotiation. The methods will always disagree. What decides your number is the team, the market cycle, and above all the proof you can show before the conversation starts. Shrink the uncertainty those methods are trying to price, and the number moves your way.